Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Botox OnabotulinumtoxinA Urinary incontinence List with criteria/condition Complete
Braftovi encorafenib Metastatic colorectal cancer Reimburse with clinical criteria and/or conditions Complete
Braftovi and Mektovi encorafenib and binimetinib Advanced Melanoma Reimburse with clinical criteria and/or conditions Complete
Brenzys Etanercept Rheumatoid arthritis, Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Breo Ellipta Fluticasone Furoate and Vilanterol (as trifenatate) Asthma List with clinical criteria and/or conditions Complete
Breo Ellipta Fluticasone furoate /vilanterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Active
Breztri Aerosphere budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Brilinta Ticagrelor Acute coronary syndromes Do not list Complete
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete
Brivlera Brivaracetam Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Chronic lymphocytic leukemia /small lymphocytic lymphoma. Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Mantle cell lymphoma (MCL) Do not reimburse Complete
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
BuTrans Buprenorphine transdermal patch Pain, moderate intensity persistent pain Do not list Complete
Byetta Exenatide Diabetes mellitus, type 2 Do not list Complete
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Complete
Bystolic Nebivolol Hypertension Do not list at the submitted price Complete
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete